Epstein Secrets

ns' ;)id:image001.png@01D1B4D 2.34B2F410 From: jeffrey E. [mailto:jPeyacationghgmatISQM) Sent Monday, Aug

ns' ;)id:image001.png@01D1B4D 2.34B2F410 From: jeffrey E. [mailto:jPeyacationghgmatISQM) Sent Monday, Augu

pital to drive shareholder return. Next catalyst will be 2Q earnings/2/116 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where s

oughts on fixed income, mandatory converts To: "Jeffrey E." <[email protected]>, Richard Kahn imacie001.

acie001.0nq image002.1pg imacte003.i0q imacie004.ipq irrapg imaqe006.iPq imaee007.ioq imacie008.ipq imaae009.Mq imaoe010.Mq imacie011.clif Jeffrey, AGN 5.5% Pfd $886.50 (6.3% strip yield) TEVA 7.0% Pfd $894.00 (7.9% strip yield) We could trade today if we can deliver into your account at MS o

pital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where

From: jeffrey E. <[email protected]> Sent: Monday, August 8, 2016 8:59 PM To: Ens, Amanda; Richard Kahn Subject: Re: Preferreds, thoughts on fixed income, man

is has a 19% 30-day vol (vs 24% for the common stock) and 30% 90-day vol (vs 41% for the common stock)= For comparison, PFF had a 4.5-5% vol. From: jeffrey =. [mailto:[email protected] <mailto:[email protected]> I Sent: Monday, August 08, 2016 4:40 PM To: Ens, Amanda Subject: Re: Preferreds, tho

apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where

onday, August 8, 2016 6:26 PM To: [email protected] Cc: Richard Kahn Subject: RE: Preferreds, thoughts on fixed income, mandatory converts Jeffrey, I continue to=like the AGN, TEVA and FTR mandatory convert preferreds. While AGN missed =n sales today, is was mostly due to noise around the last

hursday, August 04, 2016 6:30 PM To: '[email protected]' Cc: 'Richard Kahn' Subject: Preferreds, thoughts on fixed income, mandatory converts Jeffre=, Rich m=ntioned you're interested in potentially buying preferreds. While th=y still pay a decent yield, I wanted to share some thoughts about why

l to drive shareholder return. N=xt catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm :=17;s US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval=of AGN generics deal. We continue to like TEVA's positioning in generic=pharma where

From: jeffrey E. <[email protected]> Sent: Tuesday, August 9, 2016 2:23 PM To: Ens, Amanda Subject: Re: Preferreds, thoughts on fixed income, mandatory conver

tel:212.449.7781> Mobil=: 917.386.3280 <tel:917.386.3280> <javascript:_e(=78%7D,1cvmr );> </=> The power of global conne=tionr <1=> <1=> From: jeffrey =. [mailto:[email protected] <javascript:_e(%7B%7D;cvmr/jeevacation@=mail.comt> I Sent: Monday, August 08, 2016 4:14 PM To: Ens, Amanda Subject:

apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where

ns, Amanda Sent: Mond 08 2016 2:26 PM To: Cc: Richard Kahn Subject: RE: Preferreds, thoughts on fixed income, mandatory converts EFTA00821586 Jeffrey, I continue to like the AGN, TEVA and FTR mandatory convert prefeneds. While AGN missed on sales today, is was mostly due to noise around the last mi

capital to drive shareholder return. Next catalyst will be 2Q eamings/2H16 Outlook on 8/8. AGN Is on our firm's US-1 list of best Investment Ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where sc

005.jpg: imagc006.jpg: image007.jpg: image008.jpg: image009.jpg: intage010.gie imagc011.png: image003.jpg: imagc015.jpg: image016.jpg: image017.jpg Jeffrey, Rich mentioned you're interested in potentially buying preferreds. While they still pay a decent yield. I wanted to share some thoughts about why I

pital to drive shareholder return. Next catalyst will be 2Q earnings/V.116 Outlook on 8/8. AGN Is on our firm's US-1 list of best investment Ideas. Teva Pharma (TWA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where sca

PM To:'[email protected] <[email protected]> ' Cc: 'Richard Kahn' Subject: Preferreds, thoughts on fixed income, mandatory converts Jeffrey, Rich mentioned you're interested in potentially buying preferreds. While they still pay a decent yield, I wanted to share some thoughts about why

apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where

To: '[email protected] <mailto:[email protected]> ' Cc: 'Richard Kahn' Subject: Preferreds, thoughts on fixed income, mandatory converts Jeffrey, Rich mentioned you're interested in potentially buying preferreds. While they still pay a decent yield, I wanted to share some thoughts about why

apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where

To: '[email protected] <mailto:[email protected]> ' Cc: 'Richard Kahn' Subject: Preferreds, thoughts on fixed income, mandatory converts Jeffrey, Rich mentioned you're interested in potentially buying preferreds. While they still pay a decent yield, I wanted to share some thoughts about why

apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where